Literature DB >> 18502781

Migraine headache is not associated with cerebral or meningeal vasodilatation--a 3T magnetic resonance angiography study.

G G Schoonman1, J van der Grond, C Kortmann, R J van der Geest, G M Terwindt, M D Ferrari.   

Abstract

Migraine headache is widely believed to be associated with cerebral or meningeal vasodilatation. Human evidence for this hypothesis is lacking. 3 Tesla magnetic resonance angiography (3T MRA) allows for repetitive, non-invasive, sensitive assessment of intracranial vasodilatation and blood flow. Nitroglycerine (NTG) can faithfully induce migraine attacks facilitating pathophysiological studies in migraine. Migraineurs (n = 32) randomly received NTG (IV 0.5 microg/kg/min for 20 min; n = 27) or placebo (n = 5; for blinding reasons). Using 3T MRA, we measured: (i) blood flow in the basilar (BA) and internal carotid arteries (ICA) and (ii) diameters of the middle meningeal, external carotid, ICA, middle cerebral, BA and posterior cerebral arteries at three timepoints: (a) at baseline, outside an attack; (b) during infusion of NTG or placebo and (c) during a provoked attack or, if no attack had occurred, at 6 h after infusion. Migraine headache was provoked in 20/27 (74%) migraineurs who received NTG, but in none of the five patients who received placebo. The headache occurred between 1.5 h and 5.5 h after infusion and was unilateral in 18/20 (90%) responders. During NTG (but not placebo) infusion, there was a transient 6.7-30.3% vasodilatation (P < 0.01) of all blood vessels. During migraine, blood vessel diameters were no different from baseline, nor between headache and non-headache sides. There were no changes in BA and ICA blood flow during either NTG infusion or migraine. In contrast to widespread belief, migraine attacks are not associated with vasodilatation of cerebral or meningeal blood vessels. Future anti-migraine drugs may not require vasoconstrictor action.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502781     DOI: 10.1093/brain/awn094

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  63 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

Review 2.  Migraine and small vessel diseases.

Authors:  E Agostoni; A Rigamonti
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 3.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

4.  On the temporal relationship between throbbing migraine pain and arterial pulse.

Authors:  Andrew H Ahn
Journal:  Headache       Date:  2010-10       Impact factor: 5.887

5.  A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches.

Authors:  Oliver Summ; Anna P Andreou; Simon Akerman; Peter J Goadsby
Journal:  J Headache Pain       Date:  2010-10-27       Impact factor: 7.277

6.  Effects of Voluntary Locomotion and Calcitonin Gene-Related Peptide on the Dynamics of Single Dural Vessels in Awake Mice.

Authors:  Yu-Rong Gao; Patrick J Drew
Journal:  J Neurosci       Date:  2016-02-24       Impact factor: 6.167

7.  An Exploratory Study to Determine the Relationship between Cervical Dysfunction and Perimenstrual Migraines.

Authors:  Simone Horwitz; Aimee Stewart
Journal:  Physiother Can       Date:  2015       Impact factor: 1.037

Review 8.  Protecting against vascular disease in brain.

Authors:  Frank M Faraci
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

Review 9.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

Review 10.  Advanced neuroimaging of migraine.

Authors:  Todd J Schwedt; David W Dodick
Journal:  Lancet Neurol       Date:  2009-06       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.